Nuline Pharmaceuticals Expands its Distribution Network and Partners with National Sales and Marketing Company

Oct 12, 2010, 13:00 ET from Nuline Pharmaceuticals, LLC

PARSIPPANY, N.J., Oct. 12 /PRNewswire/ -- Nuline Pharmaceuticals, LLC, following up on its 2010 launch of REMESENSE™ (dipotassium oxalate 3%) TOOTH DESENSITIZER, now has expanded its pipeline to include  Amerisource Bergen, Cardinal Health and McKesson Drug. Nuline is pleased to announce it has entered into an agreement with CoreStrength, Inc., a dental sales management company, to direct its national sales and marketing efforts. Additionally, Benco Dental is utilizing its sale force to promote REMESENSE™ directly to dental professionals recognizing that over 40 million Americans experience dentin hypersensitivity.

REME•SENSE™ offers a new algorithm for dental professionals to treat dentin hypersensitivity in office and through a home use persistence program.

REME•SENSE™ (dipotassium oxalate 3%) works by reacting with calcium ions in the mouth to form insoluble calcium oxalate crystals. These crystals occlude exposed dentin tubules, thus alleviating hypersensitivity.(1)

Potassium ions are released. Potassium ions have been shown to modify nerve excitability, thus reducing the pain response.(2)

Many of the products presently on the market to treat dentin hypersensitivity mimic the natural processes (remineralization) that occur in the oral cavity. Unless the patient suffers from xerostomia, as a result of head and neck cancer treatment, Sjorgen's disease or some other condition that causes "dry mouth," these products may be of limited value.(3)

For more information, please call Dr. Gil Spector at 1-877-Nuline1 or e-mail us at info@nulinepharma.com.

(1)  Wichgers TG,Emert RL. Dentin Hypersensitivity. Gen Dent 1996;44:225-30

(2) Greenhill JD,Pashley DH. The Effects of Desensitizing Agents on Hydrualic Conductance of Human Dentin in vivo: J Dent Res. 1981

(3) Tilliss T. Addressing the Pain of Dentinal Hypersensitivity. Dimensions of Dent Hygiene: April 2010;8(4):46,48,50


SOURCE Nuline Pharmaceuticals, LLC